MR imaging evaluation of regional, remote, and global effects of percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy

Journal of Computer Assisted Tomography

Volumn 31, Issue 4, 2007, Pages 600-604

  Amano, Yasuo ^a   Takayama, Morimasa ^a   Kumita, Shinichiro ^a   Kumazaki, Tatsuo ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Hypertrophic obstructive cardiomyopathy; Magnetic resonance imaging; Percutaneous transluminal septal myocardial ablation

Indexed keywords

ABLATION;

% REDUCTIONS; CARDIAC MAGNETIC RESONANCE IMAGING; CONTRAST-ENHANCED; GLOBAL EFFECTS; GLOBAL RESPONSE; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; IMAGING EVALUATION; PERCUTANEOUS TRANSLUMENAL SEPTAL MYOCARDIAL ABLATION; REGIONAL EFFECTS; WALL THICKNESS;

MAGNETIC RESONANCE IMAGING;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTRAST ECHOCARDIOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; FEMALE; FOLLOW UP; HUMAN; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; MALE; MORBIDITY; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PERCUTANEOUS TRANSLUMINAL SEPTAL MYOCARDIAL ABLATION; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; SURGICAL TECHNIQUE;

EID: 34648815083     PISSN: 03638715     EISSN: None     Source Type: Journal    
DOI: 10.1097/rct.0b013e31803151fd     Document Type: Article

References (20)

1. Maron BJ, Bonow RO, Cannon RO, et al. Hypertrophic cardiomyopathy: interrelations of clinical manifestations, pathophysiology, and therapy. N Engl J Med. 1987;316:780-789.
2. Wigle ED, Rakowski H, Kimball BP, et al. Hypertrophi cardiomyopathy. Clinical spectrum and treatment. Circulation. 1995;92:1680-1692.
3. Marron BJ, McKenna WJ, Vogel RA, et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol. 2003;42:1687-1713.
4. Frenneaux MP. Assessing the risk of sudden death in a patient with hypertrophic cardiomyopathy. Heart. 2004;90:570-575.
5. Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet. 1995;346:211-214.
6. Lakkis NM, Nagueh SF, Kleiman NS, et al. Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. Circulation. 1998;98:1750-1755.
7. Kimmekstiel CD, Maron BJ. Role of percutaneous septal ablation in hypertrophic obstructive cardiomyopathy. Circulation. 2004;109:452-456.
8. Mazur W, Nagueh SF, Lakkis NM, et al. Regression of left ventricular hypertrophy after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation. 2001;103:1492-1496.
9. Veselka J, Honek T. Early remodeling of left ventricle and improvement of myocardial performance in patients with percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy. Int J Cardiol. 2003;88:27-32.
10. van Dockum WG, Beek AM, ten Cate FJ, et al. Early onset and progression of left ventricular remodeling after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. Circulation. 2005;111:2503-2508.
11. Amano Y, Takayama M, Amano M, et al. MRI of cardiac morphology and function after percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy. AJR Am J Roentgenol. 2004;182:523-527.
12. Seggewiss H, Gleichmann U, Faber L, et al. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients. J Am Coll Cardiol. 1998;31:252-258.
13. Moon JCC, McKenna WJ, McCrohon JA, et al. Toward risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol. 2003;41:1561-1567.
14. Kim RJ, Judd RM. Gadolinium-enhanced magnetic resonance imaging in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2003;41:1568-1572.
15. Look DC, Locker DR. Time saving in measurement of NMR and EPR relaxation times. Rev Sci Instrum. 1970;41:250-251.
16. Cerqueira MD, Weissman NJ, Dilsizian V, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation. 2002;105:539-542.
17. Kim DH, Choi SI, Chang H-J, et al. Delayed hyperenhancement by contrast-enhanced magnetic resonance imaging: clinical application for various cardiac diseases. J Comput Assist Tomogr. 2006;30:226-232.
18. van Dockum WG, ten Cate FJ, ten Berg JM, et al. Myocardial infarction after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: evaluation by contrast-enhanced magnetic resonance imaging. J Am Coll Cardiol. 2004;43:27-34.
19. Chang SM, Lakkis NM, Franklin J, et al. Predictors of outcome after alcohol septal ablation therapy in patients with hypertrophic obstructive cardiomyopathy. Circulation. 2004;109:824-827.
20. Olivotto I, Maron MS, Adabag AS, et al. Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;46:480-487.